PTC Therapeutics
PTCT
118 hedge funds and large institutions have $202M invested in PTC Therapeutics in 2016 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 22 closing their positions.
113% more call options, than puts
Call options by funds: $4.23M | Put options by funds: $1.99M
33% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 33
7% more capital invested
Capital invested by funds: $189M → $202M (+$13M)
0% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 22
1% less funds holding
Funds holding: 119 → 118 (-1)
Top Buyers
Top Sellers
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$14.4M |
| 2 |
Renaissance Technologies
New York
|
-$6.21M |
| 3 |
Millennium Management
New York
|
-$3.68M |
| 4 |
SIM
Spark Investment Management
New York
|
-$1.76M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.4M |
PTCT Hedge Fund Activity: Q2 2016 in Review
118 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2016, worth a combined $202M — up 6.9% from $189M a quarter earlier.
Fund positioning in PTCT was balanced in Q2 2016: 22 funds opened new positions, 22 closed out, 44 added to existing stakes and 33 trimmed.
The largest buyer was Pictet Asset Management (UK), adding an estimated $7.5M. The largest seller was Sectoral Asset Management, cutting an estimated $14.4M.
- 118 institutional investors held PTC Therapeutics (PTCT) as of Q2 2016, down from 119 in Q1 2016.
- Funds reported $202M of PTC Therapeutics stock for Q2 2016, up 6.9% quarter-over-quarter.
- 22 funds opened new PTC Therapeutics positions in Q2 2016 and 22 closed out, a net change of 0 holders.
- The largest PTC Therapeutics buyer in Q2 2016 was Pictet Asset Management (UK), an estimated $7.5M added.
- The largest PTC Therapeutics seller in Q2 2016 was Sectoral Asset Management, an estimated $14.4M sold.
Based on aggregated 13F filings for Q2 2016.